parp 10

PARP10-IN-2 is a potent inhibitor of PARP10, a mono-ADP-ribosyltransferase, with an IC50 value of 3.64 μM for human PARP10. It also inhibits PARP2 and PARP15, with IC50 values of 27 μM and 11 μM, respectively.

OUL232 is a potent single ARTs PARP7, PARP10, PARP11, PARP12, PARP14 and PARP15 inhibitor for cancer and tumour research.

NU1085 is a potent poly(ADP-ribose) polymerase (PARP) inhibitors have been developed that potentiate the cytotoxicity of ionizing radiation and anticancer drugs. The biological effects of NU1085 [Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer). Cells were treated with increasing concentrations of TM or TP + - NU1085 (10 microM) for 72 h.

BET-IN-20 (compound 10), a BRD4 BD1 inhibitor (IC 50 =1.9 nM), exhibits significant anticancer properties. It promotes apoptosis in acute myeloid leukemia (AML) cells and arrests the cell cycle in the G0 G1 phase. Additionally, BET-IN-20 inhibits both c-Myc and CDK6, and enhances PARP cleavage [1].

B102 (PARP HDAC-IN-1) is a dual inhibitor of PARP and HDAC, exhibiting IC50 values of 19.01 nM for PARP1, 2.13 nM for PARP2, 1.69 μM for HDAC1, and greater than 10 μM for HDAC6 in enzymatic assays. It possesses antiproliferative and antitumor properties and induces DNA damage and apoptosis in vitro.

PROTACPARP1 degrader-2 (Compound 72) is a potent PROTAC degrader of PARP, achieving a DC50 of less than 10 nM in MDA-MB-231 cells. Additionally, this compound effectively inhibits the viability of MDA-MB-436 cells with an IC50 of less than 100 nM.

OUL35 (NSC-39047) is a selective PARP-10 inhibitor, and small-molecule ARTD10 inhibitor. OUL35 has been shown to rescue cells from ARTD10-induced cell death.